Biocon Ltd 2018 AR2
The report highlights Biocon's achievements in fiscal year 2018, notably becoming the first Indian company to receive US FDA approval for its biosimilar Trastuzumab (Ogivri) and biosimilar Pegfilgrastim (Fulphila). It also marks the approval of its biosimilar Insulin Glargine (Semglee) in the EU and Australia. Financially, Biocon recorded a consolidated revenue of Rs 43,359 million, driven by a 19% growth in Research Services (Syngene). On the sustainability front, the Biocon Foundation expanded its eLAJ Smart Clinics to 21, recording nearly 230,000 patient visits, and made significant progress in the bioremediation and revival of the Hebbagodi and Yarandahalli lakes in Bengaluru.
Company: Biocon Ltd
Sector: Manufacturing
Country: India
Year: 2018
Type: AR2
Pages: 252
Back to company
Biocon Ltd
Annual Report
The report highlights Biocon's achievements in fiscal year 2018, notably becoming the first Indian company to receive US FDA approval for its biosimilar Trastuzumab (Ogivri) and biosimilar Pegfilgrastim (Fulphila). It also marks the approval of its biosimilar Insulin Glargine (Semglee) in the EU and Australia. Financially, Biocon recorded a consolidated revenue of Rs 43,359 million, driven by a 19% growth in Research Services (Syngene). On the sustainability front, the Biocon Foundation expanded its eLAJ Smart Clinics to 21, recording nearly 230,000 patient visits, and made significant progress in the bioremediation and revival of the Hebbagodi and Yarandahalli lakes in Bengaluru.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Apr 1, 2017 - Mar 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Renewable Energy
Employees